◆ NeutralAXSM
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
GlobeNewswire Inc.·
Axsome Therapeutics announced presentations of new clinical data for SYMBRAVO® (meloxicam and rizatriptan) at the American Headache Society's 68th Annual Scientific Meeting in Orlando, FL (June 4-7, 2026). Four poster presentations will showcase efficacy, safety, and comparative effectiveness data from Phase 3 trials MOMENTUM and MOVEMENT, as well as network meta-analysis comparing SYMBRAVO to gepants for acute migraine treatment.
Read Full Article at GlobeNewswire Inc. →